ES2149206T3 - Purificacion de proteinas. - Google Patents

Purificacion de proteinas.

Info

Publication number
ES2149206T3
ES2149206T3 ES93908538T ES93908538T ES2149206T3 ES 2149206 T3 ES2149206 T3 ES 2149206T3 ES 93908538 T ES93908538 T ES 93908538T ES 93908538 T ES93908538 T ES 93908538T ES 2149206 T3 ES2149206 T3 ES 2149206T3
Authority
ES
Spain
Prior art keywords
protein purification
purification
application
invention refers
receptor proteins
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93908538T
Other languages
English (en)
Inventor
Gail Folena-Wasserman
John H O'grady
Thomas M Smith
John Lifter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celldex Therapeutics Inc
Original Assignee
Avant Immunotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Avant Immunotherapeutics Inc filed Critical Avant Immunotherapeutics Inc
Application granted granted Critical
Publication of ES2149206T3 publication Critical patent/ES2149206T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/10—Selective adsorption, e.g. chromatography characterised by constructional or operational features
    • B01D15/18—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to flow patterns
    • B01D15/1864—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to flow patterns using two or more columns
    • B01D15/1871—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to flow patterns using two or more columns placed in series
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/32—Bonded phase chromatography
    • B01D15/325—Reversed phase
    • B01D15/327—Reversed phase with hydrophobic interaction
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/34—Size-selective separation, e.g. size-exclusion chromatography; Gel filtration; Permeation
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction, e.g. ion-exchange, ion-pair, ion-suppression or ion-exclusion
    • B01D15/361—Ion-exchange
    • B01D15/362—Cation-exchange
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction, e.g. ion-exchange, ion-pair, ion-suppression or ion-exclusion
    • B01D15/361—Ion-exchange
    • B01D15/363—Anion-exchange

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

ESTA INVENCION SE REFIERE A LA APLICACION DE UNA CROMATOGRAFIA DE COMBINACION A LA PURIFICACION DE PROTEINAS RECEPTORAS COMPLEMENTARIAS.
ES93908538T 1992-03-24 1993-03-24 Purificacion de proteinas. Expired - Lifetime ES2149206T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/857,022 US5252216A (en) 1992-03-24 1992-03-24 Protein purification

Publications (1)

Publication Number Publication Date
ES2149206T3 true ES2149206T3 (es) 2000-11-01

Family

ID=25324998

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93908538T Expired - Lifetime ES2149206T3 (es) 1992-03-24 1993-03-24 Purificacion de proteinas.

Country Status (19)

Country Link
US (1) US5252216A (es)
EP (1) EP0643608B1 (es)
JP (1) JP3335629B2 (es)
KR (1) KR100241172B1 (es)
AT (1) ATE193839T1 (es)
AU (1) AU659936B2 (es)
CA (1) CA2132533C (es)
DE (1) DE69328864T2 (es)
DK (1) DK0643608T3 (es)
ES (1) ES2149206T3 (es)
FI (1) FI109202B (es)
GR (1) GR3034332T3 (es)
MX (1) MX9301655A (es)
NO (1) NO310855B1 (es)
NZ (1) NZ251601A (es)
PT (1) PT643608E (es)
TW (1) TW321651B (es)
WO (1) WO1993018835A1 (es)
ZA (1) ZA932015B (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6395888B1 (en) * 1996-02-01 2002-05-28 Gilead Sciences, Inc. High affinity nucleic acid ligands of complement system proteins
DE4331358A1 (de) * 1992-10-12 1994-04-14 Braun Melsungen Ag Verfahren zur quantitativen selektiven Entfernung oder präparativen Gewinnung von Tumor-Nekrose-Faktor (TNF) oder/und Lipopolysacchariden (LPS) aus wäßrigen Flüssigkeiten
EP0812200B1 (en) * 1993-07-09 2002-02-27 Avant Immunotherapeutics, Inc. Protein purification
US5679546A (en) * 1993-09-24 1997-10-21 Cytomed, Inc. Chimeric proteins which block complement activation
US5429746A (en) * 1994-02-22 1995-07-04 Smith Kline Beecham Corporation Antibody purification
DE19515554C2 (de) * 1995-04-27 1999-06-17 Braun Melsungen Ag Verwendung eines Mittels und Vorrichtung zur simultanen extrakorporalen Elimination von Tumor-Nekrose-Faktor alpha und bakteriellen Lipopolysacchariden aus Vollblut oder/und Blutplasma
WO1997001755A2 (en) * 1995-06-26 1997-01-16 Perseptive Biosystems, Inc. High speed, automated, continuous flow, multi-dimensional molecular selection and analysis
EP1300679A3 (en) * 1995-06-26 2004-04-14 Perseptive Biosystems, Inc. Molecular selection and analysis
GB9515196D0 (en) * 1995-07-25 1995-09-20 Matthey Rustenburg Refines Interseparation of platignum group metals
ATE248631T1 (de) * 1997-06-27 2003-09-15 Life Technologies Inc Einstufige vorrichtung und verfahren zur konzentration und säuberung biologischer moleküle
US5993653C1 (en) * 1997-08-11 2001-11-06 Phenomenex Composition and column used in hplc
US6869796B2 (en) * 1997-08-26 2005-03-22 Avaris Ab Method of introducing organic molecules into target cells
US20070122904A1 (en) * 2000-09-29 2007-05-31 Unisearch Limited Method and apparatus for culturing cells
US6855263B2 (en) * 2002-07-23 2005-02-15 Nuvue Technologies, Inc. Rapid process for purification and concentration of plasmin
DE10255508A1 (de) * 2002-11-27 2004-06-17 Forschungszentrum Jülich GmbH Verfahren zur Kultivierung von Zellen zur Produktion von Substanzen
US6913695B2 (en) * 2003-07-08 2005-07-05 Bayer Healthcare Llc Sanitization of chromatographic media
WO2005012349A2 (en) * 2003-08-01 2005-02-10 Lorantis Limited Chromatographic process for the purification of notch ligands
US7329353B2 (en) * 2004-01-23 2008-02-12 Amgen Inc. LC/MS method of analyzing high molecular weight proteins
US7803931B2 (en) 2004-02-12 2010-09-28 Archemix Corp. Aptamer therapeutics useful in the treatment of complement-related disorders
AU2005263334C1 (en) * 2004-07-20 2011-01-20 Symphogen A/S A procedure for structural characterization of a recombinant polyclonal protein or a polyclonal cell line
WO2006011580A1 (ja) * 2004-07-27 2006-02-02 Genomidea, Inc. ウイルスエンベロープの精製方法
CN101039964B (zh) * 2004-08-12 2012-11-14 利普生技术有限公司 带电多糖的分级
EP1738763A1 (en) 2005-06-30 2007-01-03 AVANT Immunotherapeutics, Inc. Use of complement inhibitory proteins to treat spinal cord injury
WO2007053235A1 (en) * 2005-11-04 2007-05-10 Sachem, Inc. Cation-exchange displacement chromatography process and cationic organic compounds for use as displacer compounds in cation-exchange displacement chromatography process
CA3009846C (en) 2006-03-08 2021-08-31 David Epstein Complement binding aptamers and anti-c5 agents useful in the treatment of ocular disorders
US20100222560A1 (en) 2009-03-02 2010-09-02 Zymo Research Corporation Universal column
EP4406615A3 (en) * 2009-10-26 2024-12-11 F. Hoffmann-La Roche AG Method for the production of a glycosylated immunoglobulin
JP6092776B2 (ja) 2010-09-15 2017-03-08 セルデックス セラピューティクス インコーポレイテッド 可溶性補体受容体Ｉ型（ｓＣＲ１）を用いる慢性腎症の処置
WO2012048275A2 (en) 2010-10-08 2012-04-12 Caridianbct, Inc. Configurable methods and systems of growing and harvesting cells in a hollow fiber bioreactor system
US9649356B2 (en) 2010-10-27 2017-05-16 Celldex Therapeutics, Inc. Method of improving transplant function using soluble complement receptor type I (sCR1)
US20160090569A1 (en) 2014-09-26 2016-03-31 Terumo Bct, Inc. Scheduled Feed
US11965175B2 (en) 2016-05-25 2024-04-23 Terumo Bct, Inc. Cell expansion
US11629332B2 (en) 2017-03-31 2023-04-18 Terumo Bct, Inc. Cell expansion
US11624046B2 (en) 2017-03-31 2023-04-11 Terumo Bct, Inc. Cell expansion
AU2023293480A1 (en) * 2022-06-17 2025-01-23 CSL Innovation Pty Ltd Purification of soluble complement receptor and variants thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2319495C2 (de) * 1973-04-17 1985-01-10 Yeda Research And Development Co., Ltd., Rehovot Verfahren zum selektiven, reversiblen Binden von Biomolekülen an ein Adsorbens in einer chromatographischen Säule
US4000098A (en) * 1974-08-16 1976-12-28 Palo Alto Medical Research Foundation Separation of proteins by hydrophobic adsorption
DE3149360A1 (de) * 1981-12-12 1983-06-16 Biotest-Serum-Institut Gmbh, 6000 Frankfurt "verfahren zur reinigung und/oder phytohaemagglutinin-abtrennung von human-interleukin-2"
US4920196A (en) * 1982-07-30 1990-04-24 Genentech, Inc. Human lymphotoxin
US4908434A (en) * 1984-04-25 1990-03-13 Sloan-Kettering Institute For Cancer Research Process for preparing purified interleukin-2
US4743680A (en) * 1985-02-01 1988-05-10 New York University Method for purifying antihemophilic factor
US4894439A (en) * 1986-05-22 1990-01-16 Cetus Corporation N-terminal derivatives of tumor necrosis factor purified by microporous PTFE membranes
AU597924B2 (en) * 1985-12-11 1990-06-14 Natinco Nv Solubilization of protein aggregates
US4770781A (en) * 1986-03-03 1988-09-13 Merck & Co., Inc. Purification of human interleukin-1 species
US4771128A (en) * 1986-10-10 1988-09-13 Cetus Corporation Method of purifying toxin conjugates using hydrophobic interaction chromatography
AU609824B2 (en) * 1987-06-15 1991-05-09 Southern Cross Biotech Pty Ltd. Production of proteins in active forms
US4981799A (en) * 1987-08-21 1991-01-01 Takeda Chemical Industries, Ltd. Acylamino acid racemase, production and use thereof
US4765903A (en) * 1987-10-06 1988-08-23 Interferon Sciences, Inc. Purification of monomeric interferon
US5159063A (en) * 1989-02-02 1992-10-27 The United States Of America As Represented By The Department Of Health And Human Services Isolation and characterization of a 120 kda glycoprotein plasma
US5030352A (en) * 1990-01-25 1991-07-09 Purdue Research Foundation Coated media for chromatography

Also Published As

Publication number Publication date
EP0643608A1 (en) 1995-03-22
WO1993018835A1 (en) 1993-09-30
NO310855B1 (no) 2001-09-10
JP3335629B2 (ja) 2002-10-21
US5252216A (en) 1993-10-12
ZA932015B (en) 1994-09-21
KR950700779A (ko) 1995-02-20
MX9301655A (es) 1994-03-31
EP0643608B1 (en) 2000-06-14
AU3932493A (en) 1993-10-21
FI944412A0 (fi) 1994-09-23
PT643608E (pt) 2000-11-30
AU659936B2 (en) 1995-06-01
CA2132533A1 (en) 1993-09-30
FI944412L (fi) 1994-09-23
JPH07505469A (ja) 1995-06-15
NO943546L (no) 1994-11-23
EP0643608A4 (en) 1997-11-26
CA2132533C (en) 2004-01-13
NZ251601A (en) 1997-03-24
ATE193839T1 (de) 2000-06-15
GR3034332T3 (en) 2000-12-29
FI109202B (fi) 2002-06-14
DE69328864T2 (de) 2000-12-14
DK0643608T3 (da) 2000-10-02
TW321651B (es) 1997-12-01
DE69328864D1 (de) 2000-07-20
KR100241172B1 (ko) 2000-02-01
NO943546D0 (no) 1994-09-23

Similar Documents

Publication Publication Date Title
ES2149206T3 (es) Purificacion de proteinas.
PT746398E (pt) Purificacao de anticorpos
HN1997000166A (es) 1-arilpirazoles plaguicidas
HN1998000086A (es) Derivados de 9 - desofo - 9 aza - 9a - homoeritromicina a - c - 4 sustituidos.
HN1997000126A (es) Derivados de indazol
HN1998000132A (es) Combinaciones terapeuticas
HN1997000023A (es) Derivados de lactama
PT875252E (pt) Formulacoes de proteina c activada
HN1997000090A (es) Compuestos de piridilpirrol
ES2076999T3 (es) Peptidos anticoagulantes radiomarcados.
ES2193197T3 (es) Craquizacion catalitica com mcm-49.
MX9302614A (es) Receptor de glutamato metabotropico humano y compuestos de dna relacionados.
BR9812773A (pt) "alfa-amino-epsilon-caprolactamas policìclicas e compostos relacionados"
ITRM920658A0 (it) Procedimento per la purificazione della proteina endotelina
NO991175D0 (no) Anvendelse av proteiner som midler mot autoimmune sykdommer
HN1998000102A (es) Composiciones solubilizadas de sertralina
ES2094228T3 (es) Peptidos anticoagulantes.
FI946031A7 (fi) Kringleä sisältävien proteiinien puhdistus ja etenkin t-PA:n
HN1998000078A (es) Sal tartrato de un dipeptido sustituido.
HN1997000354A (es) Nucleosidas terapeuticas
HN1998000014A (es) Metodo de purificacion de 1,3,5, trii sopropilbenceno
MX9603809A (es) Preparado combinado farmaceutico con ketoprofeno.
ITMI931263A1 (it) Intermedi per la preparazione di peptidi retro-inversi
HN1996000127A (es) Encendedor
HN1998000131A (es) Terapia de combinación

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 643608

Country of ref document: ES